PDCD1 and melanoma: In addition, previous studies have focused on NSCLC and melanoma, in which anti-PD-1 immunotherapy has been extensively used; this is the first study to focus on nonmetastatic NPC, in which anti-PD-1 immunotherapy is still in the clinical trial stage.